Close Menu

NEW YORK (360Dx) – T2 Biosystems announced today that it has priced a public offering of 6.1 million shares of its common stock at a public offering price of $7.50 per share, bringing in gross proceeds of roughly $45.8 million.

T2 Bio said that it will grant the underwriters a 30-day option to purchase up to an additional 915,000 shares of its common stock at the public offering price. The firm expects the offering to close around June 4.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.